306776-79-4
Chemical Structure
DOTA-GA(tBu)4
- CAS No.: 306776-79-4
- Formula:C35H64N4O10
- Molecular Weight:700.90
IUPAC Name: 5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoic acid
InChIKey: SUAUFMLRKFUOID-UHFFFAOYSA-N
SMILES: O=C(CCC(N1CCN(CCN(CCN(CC1)CC(OC(C)(C)C)=O)CC(OC(C)(C)C)=O)CC(OC(C)(C)C)=O)C(OC(C)(C)C)=O)O
Biological Activity: DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA-GA(tBu)4 | 98.69% | DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
